CIK 0001176309
- Non-accelerated filer
- Smaller reporting company
ORAMED PHARMACEUTICALS INC.
Sign in to watch- Ticker
- ORMP
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 980376008
- Phone
- +1 646-844-1164
- Business address
- 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY, 10036
- Former names
- Integrated Security Technologies, Inc., IGUANA VENTURES LTD
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $225,530
- in 2 filings, $226K under 10b5-1 plans
Net −$225,530. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-01-04 | Silberman David Chief Financial Officer | Grant or award | +136,500 | 366,500 | ||
| 2023-05-26 | Silberman David Chief Financial Officer | Grant or award | +24,500 | 230,000 | ||
| 2023-04-17 | Silberman David Chief Financial Officer | Grant or award | +97,500 | 205,500 | ||
| 2022-07-28 | Silberman David Chief Financial Officer | Grant or award | +39,000 | 108,000 | ||
| 2022-01-03 | Silberman David Chief Financial Officer | Grant or award | +19,000 | 69,000 | ||
| 2022-01-03 | Silberman David Chief Financial Officer | Grant or award · Stock Option (right to buy) | +32,000 | 32,000 | ||
| 2021-09-01 | Silberman David Chief Financial Officer | Grant or award | +50,000 | 50,000 | ||
| 2021-09-01 | Silberman David Chief Financial Officer | Grant or award · Stock Option (right to buy) | +50,000 | 50,000 |
Page 1 of 1 · 8 trades